✨ Free AI Report
Pharming Group N.V.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Pharming Group N.V.
Company Research

Pharming Group N.V.: Business Overview, Financials & Competitive Analysis

Pharming Group N.V. scores 7/10 on the AskCyborg Cyborg Score (Strong). Rare disease specialist with market validation and clinical pipeline acceleration positioning for sustainable growth trajectory. Pharming demonstrates strong growth momentum with its September 2025 promotion to the Euronext AMX mid-cap index. The company has a focused rare disease strategy with key pipeline catalysts including leniolisib for primary immunodeficiencies, though.

What is Pharming Group N.V.'s industry? Pharming Group N.V. (pharming.com) operates in Biopharmaceuticals - Rare Diseases. AskCyborg classifies Pharming Group N.V. under Biopharmaceuticals - Rare Diseases in its company registry.

Pharming Group N.V. is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases, commercializing and developing a portfolio of innovativ...

7/ 10Strong

Cyborg Score thesis

Rare disease specialist with market validation and clinical pipeline acceleration positioning for sustainable growth...

Read the full analyst-debate transcript →
Industry Biopharmaceuticals - Rare Diseases
3 named competitors
4 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 21, 2026
AI-Verified Research
30+ Page Report

Get the Latest Pharming Group N.V. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for Pharming Group N.V.

AskCyborg analysts argue the bull and bear cases for Pharming Group N.V. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Pharming Group N.V. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

Pharming Group N.V. Overview

Pro stress-test →

Pharming Group N.V. is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases, commercializing and developing a portfolio of innovative medicines including small molecules and biologics. The company is headquartered in Leiden, the Netherlands, and serves patients in over 30 markets globally.

Strategic Profile

Pro stress-test →

Pharming's promotion to the AMX mid-cap index in September 2025 reflects the company's strong growth momentum. The company is focused on executing significant commercial and pipeline catalysts to develop into a leading global rare disease company.

Competitive Landscape

Pro stress-test →

Pharming's lead commercial product RUCONEST is a recombinant human C1-esterase inhibitor for hereditary angioedema treatment. The company competes in the rare disease space with focused portfolios targeting unmet needs in immunodeficiency and complement-mediated disorders, competing against larger pharma and specialty biotech firms with similar disease focus.

Industry Context

Pharming Group N.V. operates in Biopharmaceuticals - Rare Diseases.

Key facts

Founded: 1988 · Headquarters: Leiden, Netherlands

What the analysts stress-tested

The top findings that survived the multi-agent debate for Pharming Group N.V..

  • Promoted to AMX mid-cap index (September 2025) signaling strong commercial and financial momentum
  • Leniolisib in accelerated FDA review pathway for pediatric rare immunodeficiency (APDS)
+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • February 2026FDA Complete Response Letter for leniolisib indicating regulatory pathway challenge
  • December 2025Participation in Oppenheimer Movers in Rare Disease Summit showcasing HAE market leadership
  • +2 moreTrack every material event for Pharming Group N.V. as it happens. Explore monitoring →
Get alerted when Pharming Group N.V. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Berinert/C1-esterase inhibitorPlasma-derived C1-esterase inhibitor for acute HAE attacks→CinryzeC1-esterase inhibitor concentrate for hereditary angioedema prophylaxis→Kallikrein inhibitorsAlternative mechanism for HAE and rare disease management→

Compare Pharming Group N.V. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Pharming Group N.V. operates in Biopharmaceuticals - Rare Diseases. See how the rest of the sector scores on the Cyborg framework.

Browse Biopharmaceuticals - Rare Diseases research →
NEW · MCP server

Ask your AI assistant about Pharming Group N.V.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Pharming Group N.V. and its top competitor on Cyborg Score”
“What did Pharming Group N.V. do this quarter?”
“Is Pharming Group N.V. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does Pharming Group N.V. do?+
Pharming Group N.V. is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases, commercializing and developing a portfolio of innovativ...
What is Pharming Group N.V.'s Cyborg Score?+
Pharming Group N.V. has a Cyborg Score of 7/10 (Strong). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Pharming Group N.V.'s main competitors?+
Named competitors include Berinert/C1-esterase inhibitor, Cinryze, Kallikrein inhibitors. The full competitive landscape is in the AskCyborg report.
How can I get the full Pharming Group N.V. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Pharming Group N.V. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Pharming Group N.V. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Biopharmaceuticals - Rare Diseases research

Companies in the same sector and named competitors, ranked by Cyborg Score.

8Pharvaris N.V.